External Link

You are now leaving the Grünenthal website. You will be re-directed to an external website. Grünenthal accepts no responsibility for the content of other websites.

Grünenthal is a global leader in pain management and related diseases.

We have a long track record of bringing innovative treatments to patients worldwide. As a fully integrated pharmaceutical company, we cover the entire value chain – from drug research and development to commercialisation of portfolios with growth products and established medicines. We operate in accordance with the highest ethical and regulatory standards. At Grünenthal, we focus our efforts on our vision of a World Free of Pain.

Aachen Campus_411 (2)

Grünenthal at a glance

Our virtual company showcase provides information about our key objectives and activities, as well as our recent business development highlights and financial performance.

Strong and capable team

4,100

employees worldwide

Solid revenue base

1.8

billion euro in 2025

Commercial presence in

28

across Europe, Latin America and the US

Products sold in around

100

countries

International network

2

R&D sites – one R&D Unit in Aachen (Germany) and an Innovation Hub in Boston, (USA)

Production capacities

5

manufacturing sites in Europe and Latin America

Elderly female patient with crutches

Our unique commitment

For over 50 years, we have been a pioneer in pain treatments, tackling critical unmet medical needs and bringing us closer to our vision of a World Free of Pain.

Our lead projects in research – Picture of the Grünenthal Glucocorticoid Receptor Modulator (GRM)

Pipeline

Our scientists have developed several life-changing pain medicines for patients. To move closer to our vision of a World Free of Pain, we are pursuing a range of programs across different modalities, targets, and mechanisms of action.

Contract Manufacturing “GRT PRO" - Grünenthal Employee in our production plant

Global capabilities

Grünenthal operates five world-class manufacturing sites around the globe, where we produce all of our own products, as well as manufacturing medicines for key industry partners. We have made significant investments into our facilities and are fully committed to ensuring the quality, safety and sustainability of every medicine we produce for patients.

MSCI recognises Grünenthal as an ESG industry leader" role. MSCI Provisional ESG Ratings (p) AA as of Oct. 2025

ESG Industry Leader

At Grünenthal, conducting our business responsibly is an integral part of our company’s strategy and culture. We aspire to create a positive impact for society – in our core business and beyond. We are guided by integrity, transparency and the highest ethical standards. Our industry-leading way of doing business responsibly is reflected in our external Environment, Social and Governance (ESG) ratings.